Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL - a preliminary study on a Polish population
The association of single‐nucleotide polymorphisms (SNPs) of B‐cell activating factor (BAFF)/a proliferation‐inducing ligand (APRIL) system with B‐cell chronic lymphocytic leukemia (B‐CLL) have been suggested, therefore, we investigated 20 SNPs of BAFF, APRIL, BAFF‐R, transmembrane activator and cal...
Saved in:
Published in | Tissue antigens Vol. 86; no. 4; pp. 279 - 284 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.10.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The association of single‐nucleotide polymorphisms (SNPs) of B‐cell activating factor (BAFF)/a proliferation‐inducing ligand (APRIL) system with B‐cell chronic lymphocytic leukemia (B‐CLL) have been suggested, therefore, we investigated 20 SNPs of BAFF, APRIL, BAFF‐R, transmembrane activator and calcium modulator and cyclophilin‐ligand interactor (TACI), B‐cell maturation antigen (BCMA) genes and the risk and outcome of B‐CLL in 187 patients and 296 healthy subjects as well as ligand‐receptor gene × gene interactions. Although the obtained P‐values for all 20 SNPs did not reach statistical significance for this study (α = 0.003), the high value of the global chi‐squared statistic (χ2df = 38 = 52.65; P = 0.0586), and obtained values of odds ratio indicate that rs9514828 (BAFF), rs3803800 (APRIL) and rs4985726 (TACI) may be associated with the risk of B‐CLL. We observed that the B‐CLL patients with the genotype rs9514828CT/rs11570136AA were diagnosed with the disease 12 years later than the whole group of patients in this study. |
---|---|
Bibliography: | Fig. S1. Expected means of the age at diagnosis in group of patients according to the mean number of allele C of rs9514828 of B-cell activating factor (BAFF) and the mean number of allele A of rs11570136 of B-cell maturation antigen (BCMA) per person in the group.Table S1. Genotype distribution of the B-cell activating factor (BAFF) (TNFSF13B; 13q33.3) polymorphisms in patients and controlsTable S2. Genotype distribution of the a proliferation-inducing ligand (APRIL) (TNFSF13; 17p13.1) polymorphisms in patients and controlsTable S3. Genotype distribution of the transmembrane activator and calcium modulator and cyclophilin-ligand interactor (TACI) (TNFRSF13B; 17p11.2) polymorphisms in patients and controlsTable S4. Genotype distribution of the BAFF receptor (BAFF-R) (TNFRSF13C; 22q13.2) polymorphism in patients and controlsTable S5. Genotype distribution of the B-cell maturation antigen (BCMA) (TNFRSF17; 16p13.13) polymorphisms in patients and controlsTable S6. Conditional and marginal means, standard deviations (SD) and ranges (minimum-maximum) of age at diagnosis according to B-cell activating factor (BAFF) rs9514828 and B-cell maturation antigen (BCMA) rs11570136 polymorphisms ArticleID:TAN12641 istex:A829C4E8B233E088DCBDDD9505CB69CD3DEEA736 ark:/67375/WNG-2FGNP3GK-5 National Science Centre Poland - No. N N402 680940 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0001-2815 1399-0039 |
DOI: | 10.1111/tan.12641 |